The use of fosfomycin has been limited in therapeutics in recent years. Because it has shown good antibacterial activity in vitro and clinical efficacy in some domains, it has been proposed as an alternative to current antimicrobial agents, which are subject to increasing resistance. This paper reviews the main properties of fosfomycin and the latest publications concerning multidrugresistant Enterobacteriaceae infections. In uncomplicated urinary tract infections, a single oral dose was found to be safe and effective. In complicated urinary tract infections, the same results were observed with several doses. In both cases, by using fosfomycin to treat infections, the use of carbapenems could be reduced, leading to lower costs and better microbial ecology. In severe infections, combinations with intravenous fosfomycin need to be explored further because its future activity may depend on choosing a good partner drug. Because of the fast evolution of microbial resistance, more studies are urgently needed.
Introduction
Increased antibiotic resistance in Enterobacteriaceae is now a major concern worldwide. [1] [2] [3] [4] [5] [6] [7] Resistance is generally encoded by plasmidic or chromosomal genes which are easily transferred from one bacterium to another, without any consideration of species or genus limits. These transfers are generally of interest to microbiologists trying to discover the new β-lactamase able to hydrolyze all the β-lactam antibiotics, carbapenems included. This enzyme will be more devastating if its gene is incorporated into an integron capable of encoding resistance to all the antibiotics commonly used in therapeutics. [8] [9] [10] [11] For practical purposes, a bacterial strain is said to be multidrug-resistant if it is resistant to at least three classes of potentially active antibiotics. It is said to be extensively drug-resistant if it is resistant to all but one or two antimicrobial agents.
Far from these descriptions, fosfomycin still exhibits good antibacterial activity, [12] [13] [14] [15] [16] [17] mainly because its use has been limited in therapeutics. This underutilization was probably due to early problems in determining its true in vitro activity, 15 demonstrating its efficacy as a single agent, 15, 18 and the resulting lack of inclination of pharmaceutical companies to perform clinical studies of fosfomycin in combination regimens. As a consequence of its spectrum of activity, low percentage of resistance, bactericidal effect, and pharmacokinetic properties, a single 3 g dose taken orally has been shown to be generally safe and effective in the treatment of lower urinary tract infections. Moreover, parenteral administration may be useful in the treatment of severe infections. Because multidrug-resistant Enterobacteriaceae are often responsible for these infections, not only in hospitals but also in the community, we have to bear these pathogens in mind, because secondary bacteremia may occur if treatment is not effective. We undertook this review to consider the place of fosfomycin in the treatment of these infections, because it has been recommended by many authors.
15,19-24

Pharmacokinetics and Pharmacodynamics Description
Fosfomycin is a small hydrophilic molecule (molecular weight 138 Da in its acidic form) that has two unusual features in its configuration, ie, an epoxy ring responsible for its antibiotic activity and a direct carbon-phosphorus link. 25 It is available principally as a disodium salt and as a trometamine (or trometamol) salt (Fig. 1) . Initially released by a few bacterial species, such as Streptomyces spp [26] [27] [28] or Pseudomonas syringae, 29 it is now produced synthetically for pharmaceutical purposes. The disodium salt is administered parenterally and the trometamine salt orally.
Fosfomycin has a broad spectrum of activity against aerobic bacteria. It acts as an analog of phosphoenolpyruvate by inactivating the bacterial enzyme, enolpyruvatetransferase. Because this target is very specific to the bacterial wall, fosfomycin is not metabolized in mammals. 30, 31 In spite of its wide spectrum of antibacterial activity, pharmaceutical development of the molecule has been limited as a consequence of difficulties in determining its in vitro activity 15 and its clinical efficacy. 18, 32 These issues have led to restricted therapeutic use of fosfomycin as a single agent. However, at the present time, when there is a shortage of antibiotic research and a dramatic development of antimicrobial resistance, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] previous prescribing habits must be reconsidered and better use made of the old antimicrobial agents, like fosfomycin.
Pharmacokinetics of intravenous fosfomycin
After intravenous administration, the graphic representation of fosfomycin concentrations in the blood as a function of time shows an exponential trajectory (fast disposition phase) followed by a rectilinear phase (slow distribution phase). 25, 30, 31 This pattern is characteristic of a bicompartmental model. A cumulative effect is observed after multiple doses. 31, 43 The main pharmacokinetic parameters are presented in Table 1 . Serum protein binding is estimated at below 3%, which allows a large tissue availability. 29, 44 The half life in serum is long, principally because of the slow renal clearance of fosfomycin. The apparent volume of distribution is large, suggesting good diffusion into interstitial fluid and access to infected tissues. The results of several studies showing fosfomycin distribution in the body after intravenous infusion are presented in Table 2 . High bone and lung diffusion suggests that the drug would be effective in treating bone and lung infections. It should be noted that fosfomycin concentrations in cerebrospinal fluid are much greater during the acute phase of meningitis than in the absence of inflammation. 31, 45 Moreover, fosfomycin concentrations in amniotic fluid, fetal blood, colostrum, and milk were 45%, 18%, 5%, and 4%, respectively, of blood concentrations. 30 Fosfomycin is almost completely eliminated by glomerular filtration, and 80%-95% of the dose is recovered unchanged in urine within 24 hours. 25, 44 Bile concentrations of fosfomycin were observed to be 6% and 21% of blood concentrations in the studies by Kirby 30 and by Bando and Toyoshima, respectively. 46 Reduced renal function increases serum peaks and lengthens the plasma elimination half-life because fosfomycin is mostly eliminated by glomerular filtration. 47 When creatinine clearance is below 50 mL/min, the dose should be reduced by 50%. 48 The high prevalence of renal impairment in the elderly may require dose adjustment. Impairment of hepatic function has little impact on the plasma elimination half-life of fosfomycin. 44 In spite of 40 years of evolution of methods to determine fosfomycin concentrations, there has been almost no progress in lowering the limit of sensitivity of the assays, which is approximately 1 mg/L by gas chromatography 43, 49, 50 or by capillary gas chromatography, 51, 52 while by microbiological methods, it is reported to be 0.7-1.5 mg/L when mentioned. 47, 48, 53, 54 
Pharmacokinetics of fosfomycin trometamine
The calcium salt of fosfomycin was quickly abandoned because of its low bioavailability, and the trometamine salt was preferred for its stability and better absorption. 44, 48, 53 Fosfomycin trometamine is thought to dissociate into fosfomycin acid and trometamine at the absorption stage, 55 and then fosfomycin absorption is mediated via the intestinal phosphate transport system. 56 After a single dose of fosfomycin 3 g, the bioavailability ranges from 34% to 58%, 31, 44, 53, 55, 57 with a peak plasma concentration ranging from 12 to 32 mg/L and a delay of 2-4 hours. Because fosfomycin is not metabolized and the nonrenal clearance is negligible, 30 the main route of excretion is in the urine. Shortly after the peak in serum, the peak of excretion is observed, with urinary concentrations in the range 1000-4000 mg/L within four hours. Elimination is prolonged, with mean concentrations above 128 mg/L for more than 24 hours. 52, 53 The concentration achieved in urine is the main criterion for the break points chosen by the Clinical and Laboratory Standards Institute. 58 When fosfomycin is taken with food, the peak urinary concentration is lower and appears later. 59, 60 Most of the unabsorbed fosfomycin is recovered unchanged in feces. 61 This property is exploited in Japan for the treatment of enteritis 62 and hemorrhagic enterocolitis. [63] [64] [65] The main pharmacokinetic parameters of fosfomycin trometamine are presented in Table 3 .
Pharmacodynamic features
According to Matzi et al 52 fosfomycin shows concentration-dependent bactericidal activity on killing curves. After two hours of exposure to different concentrations of the antibiotic, these authors observed a postantibiotic effect in the range of 3.2-4.7 hours. According to Pfausler et al 43 optimal killing is time-dependent, but requires fosfomycin concentrations at least eight times the minimum inhibitory concentration (MIC) in the medium. In a study in which Gram-negative infected catheters were treated with fosfomycin or other antibiotics alone or in combination, no regimen was able to eliminate the organisms. 66 Concerning neutrophil function against Escherichia coli, it has been shown that fosfomycin increased intracellular bactericidal activity, intracellular calcium concentration, and extracellular reactive oxygen intermediate production, did not affect neutrophil phagocytosis, intracellular reactive oxygen intermediate production, or chemokinesis, and decreased chemotaxis. 67 In a comparison of the ability of antimicrobial agents to modulate the oxidative burst of polymorphonuclear neutrophils triggered by formylmethionylleucyl-phenylalanine, fosfomycin had no effect, while antibiotics of the penicillin class (with a 6-aminopenicillanic acid nucleus) had an inhibitory effect, and antibiotics of the cephalosporin class (with a 7-aminocephalosporanic acid nucleus) and ofloxacin showing an enhancing effect. 68 In another study of the immunomodulatory effects of fosfomycin in experimental human endotoxemia, it was concluded that the protein and mRNA levels of tumor necrosis factor, interleukin-1β, and interleukin-6 were almost identical with or without fosfomycin.
69
Drug interactions
Absorption of fosfomycin trometamine is decreased by metoclopramide and by drugs that stimulate digestive motility, but is not affected by cimetidine. 61 In healthy volunteers, probenecid lowers the renal clearance of fosfomycin, suggesting the existence of tubular secretion.
70
Several miscellaneous studies have demonstrated the experimental efficacy of fosfomycin in reducing or preventing ototoxicity and/or nephrotoxicity of Notes: *25 mg/kg; **50 mg/kg. Abbreviations: n, number of patients; H, healthy; Y, young adult (26-33 years); E, elderly adult (65-82 years); ri, renal insufficiency; I (CL cr = 30-80 mL/ min); ii, CL cr = 10-30 mL/min; iii, CL cr = 2-10 mL/min; iv, hemodialysis; F, fasting; AM, after meal; P, patient; C max , maximum plasma drug concentration; t max , time to C max ; t 1/2β , plasma elimination half-life; AUC ∞ , area under plasma concentration-time curve to infinity; Fu, percentage of fosfomycin excreted unchanged in the urine after (time of study in hours).
some drugs, including cyclosporine, cisplatinum, and certain antibiotics, eg, the aminoglycosides, 71, 72 vancomycin, polymyxin B, and amphotericin B. This efficacy has also been observed in clinical practice. [73] [74] [75] Detailed reviews have been published elsewhere. 30, 61 Several hypotheses have been made to explain this protective effect with aminoglycosides, including competition for entry that would prevent accumulation and toxicity 71, 72 and stabilization of lysosomal membranes. 76 
Antibacterial Activity Spectrum of activity
Fosfomycin has a broad spectrum of activity which is interpreted differently according to the break points chosen and the method used for susceptibility testing. Table 4 presents the in vitro activity against the main pathogens of the urinary tract reported in various publications. 
Mechanism of action
Classically, fosfomycin enters bacterial cells by two active pathways, ie, the glycerophosphate transport system which is partly constitutive but antagonized by the phosphate ion, and by the hexose phosphate uptake system that is inducible (ie, not expressed in the absence of a competent inducer, eg, glucose-6-phosphate). The glycerophosphate transport system is widespread in the bacterial world, while the hexose phosphate uptake system is confined to Staphylococcus spp and Enterobacteriaceae (with the exception of Proteus spp).
85-87
Once inside the cell, fosfomycin acts as an analog of phosphoenolpyruvate and inhibits enolpyruvyl transferase (also known as MurA), a cytoplasmic enzyme that allows the first step of synthesis of N-acetylmuramic acid. 86, [88] [89] [90] [91] Because N-acetylmuramic acid is a major component of glycan strands in the cell wall, fosfomycin blocks cell wall synthesis with a lethal effect.
86,92,93
Mechanisms of resistance
In spite of the broad spectrum of fosfomycin antibacterial activity, several species are naturally resistant and in some of these the mechanism of resistance has been identified. The resistance of enolpyruvyl transferase to inactivation by fosfomycin was demonstrated in Mycobacterium tuberculosis, 94 Vibrio fisheri, 95 and Chlamydia trachomatis.
91
In susceptible organisms, several mutations in murA demonstrate a lower affinity of its product to phosphoenolpyruvate and may lead to fosfomycin resistance [96] [97] [98] associated with a lower rate of peptidoglycan synthesis. 98 However, resistance to fosfomycin due to overexpression of enolpyruvyl transferase has been also observed.
96
Several modifying enzymes have been described, sometimes in species that could produce this antibiotic, 99 but also in strains that harbor plasmidic or chromosomal resistance. In all cases, they lead to the formation of inactive adducts:
• FosA is a metalloenzyme. It opens the epoxide ring of fosfomycin and forms a covalent bond between the sulfhydryl residue of the cysteine in glutathione and the C-1 of fosfomycin. [100] [101] [102] This type of resistance has been found in some Gram-negative strains (Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp), 103 where it is either encoded by plasmids or by the chromosome. 104 It is worth underlining the important similarities between the DNA of these genes and those of several strains of Streptomyces spp.
99
• FosB allows the formation of L-cysteinefosfomycin. This type of resistance has been found in Gram-positive species only, either encoded by plasmids in Staphylococcus spp, 103, 105, 106 or by the chromosome in Bacillus subtilis. 107 Because the amino acid sequence of FosB is 48% identical to that of FosA, a common origin is likely. 106, 107 • FosC allows fosfomycin phosphorylation with ATP as a cosubstrate. It has been described in P. syringae, a species that naturally produces fosfomycin.
29
A similar mechanism has been described with fomA and fomB in Streptomyces wedmorensis, 108 and with rare strains of P. aeruginosa.
109
• FosX leads to a water adduct. It has been described in Mesorhizobium loti and Listeria monocytogenes. [110] [111] [112] Mutations in transport systems (glpT or uhpT) are easily observed in laboratory studies, and lead to a decrease in uptake of the drug, and thus resistance to fosfomycin. 85, 86, 113, 114 They may be associated with mutations in their regulatory genes, such as uhpA (encoding a regulator protein required for activation of the uhpT promoter), or ptsI and cyaA, the products of which are involved in the synthesis of cyclic AMP and therefore regulate the level of glycerophosphate transport.
96,114-116
Although many mechanisms of resistance to fosfomycin have been described since its discovery, mutations of fecal E. coli strains during treatment of uncomplicated acute cystitis do not appear to be clinically relevant, which sets them apart from the fluoroquinolones. 117 For some authors, the observation that fosfomycin resistance does not increase with the passage of time could be due to the fact that mutations in murA and in transport systems have a biological cost which is not compatible with their persistence in the community. 114, 118, 119 But another concern about the lack of development of fosfomycin resistance must be considered, ie, that it has been little used in the past, either in human or animal therapies.
120
Considering the present status of its susceptibility, fosfomycin often appears to be an interesting therapeutic option for the treatment of multidrug-resistant Enterobacteriaceae, 9 in vitro susceptibility testing and interpretative standards Susceptibility testing for fosfomycin may be performed by the agar disk diffusion method, the gradient diffusion method (Etest ® , AB Biodisk, Solna, Sweden), the agar or broth dilution method, or by the break point dilution method. Unfortunately, for many reasons, fosfomycin susceptibility results were not reported in many of the publications dealing with multidrug-resistant bacteria.
130-132
The results of in vitro susceptibility testing may be influenced by many factors. In particular, phosphate ions are able to inhibit the glycerophosphate transport system, while a high concentration of dextrose represses the hexose phosphate uptake system, therefore false resistant results may be reported if the medium does not include an inducer for the hexose phosphate uptake system. 86, 93, 133 In correct for this, the practice of adding glucose-6-phosphate to Mueller Hinton medium was generally adopted. For practical purposes, this may be achieved either by adding glucose-6-phosphate 25 mg/L to the agar for MIC determinations, or by loading fosfomycin susceptibility discs with glucose-6-phosphate 50 µg.
133, 134 The antibacterial activity of fosfomycin is enhanced when pH decreases from 7.9 to 5.5 133 and in an anaerobic atmosphere.
135-137
Probably because mutations are better expressed in a liquid medium, MIC determinations in broth were thought to be too high compared with agar determinations, 138 but it is possible to find good agreement between broth and agar determinations if a faint haze of growth is ignored in a liquid medium. 87 MIC determinations may be equally influenced by the size of the inoculum or the way it was prepared.
93
The clinical significance of the role of glucose-6-phosphate in penetration of the bacterial cell by fosfomycin has been debated because glucose-6-phosphate is known to be absent in sterile urine, 139 in normal cerebrospinal fluid, 140 and in the intestine, 141 but it is present in normal serum at a concentration of 4 ± 1 mg/L, 141 and in lysed red blood cells at a concentration of 3.9-7.8 mg/L. 86 Therefore, glucose-6-phosphate must be considered to be a potential inducer of fosfomycin uptake at infection sites if there is an effusion of serum or red blood cells. In contrast, urine is normally the physiological elimination route for phosphate ions that are not incorporated into bone. The amount of phosphorus eliminated may vary from 1 g to 5 g per day, and this may inhibit the entry of fosfomycin into bacterial cells which naturally lack the hexose phosphate uptake system.
Generally, there is a good correlation between disc susceptibility tests and MICs, but some discrepancies have been observed with Klebsiella pneumoniae strains, especially when extended-spectrum β-lactamase-producing strains were assessed, even with Etest determinations. 9, 142, 143 This observation is of concern because meaningful evaluation of clinical studies requires accurate data on in vitro susceptibility.
According to the Clinical and Laboratory Standards Institute, taking into account the concentrations observed in urine after a single oral dose of fosfomycin trometamol, a strain is considered as susceptible, intermediate, or resistant if its MIC is # 64, =128, or $256 mg/L, respectively. 58 When considering blood and tissue concentrations observed after intravenous administration, according to the European Committee on Antimicrobial Susceptibility Testing, a strain is considered susceptible if its MIC is # 32mg/L and is considered resistant if its MIC is . 32mg/L. 144 The same break points are used for oral administration of the drug.
Activity against multidrug-resistant strains of Enterobacteriaceae
Because bacterial resistance to fosfomycin is rarely observed in outbreaks of multidrug resistance, its activity against various pathogens has been extensively studied in the last decade. The results of a few such studies are presented in Table 6 . In several of these, the number of strains observed is limited, so they have no true statistical value because some isolates might be genetically related.
in vitro synergism
As a consequence of the occurrence of resistant mutants during treatment, it was difficult to use fosfomycin as a single agent, 32 so combinations with other antibiotics were soon considered, especially for the treatment of multiresistant strains.
146-150
In studies that considered the effect of a combination of fosfomycin with cefotaxime, ceftriaxone, ceftazidime, or aztreonam against a series of strains with known patterns of resistance, a synergistic effect (fractional inhibitory concentration [FIC] index #0.5) was observed with more than 50% of strains of Enterobacteriaceae when they produced a cephalosporinase (E. coli, Enterobacter cloacae, Serratia marcescens, Serratia liquefaciens, and Proteus vulgaris), 151, 152 excepted M. morganii and Providencia stuartii, 152 while the effect was mostly Abbreviations: MDR, multidrug resistant (resistant to at least three classes of antibiotics); eSBL, extended spectrum β-lactamase; M-BL, metallo-β lactamase; Au, Austria; Gr, Greece; HK, Hong Kong (China); Sp, Spain; Tk, Turkey; UK, United Kingdom; USA, United States of America.
additive (1 $ FIC index . 0.5) against strains that produced a penicillinase (E. coli, K. pneumoniae, and Proteus mirabilis). 152 This kind of combination was successfully used for parenteral treatment of a few severe infections in critically ill patients, mainly due to Staphylococci, [153] [154] [155] [156] but sometimes due to resistant Enterobacteriaceae. 45 Few other data are available on multiresistant strains of Enterobacteriaceae. 157 A synergistic effect of fosfomycin against S. marcescens was observed when combined with mezlocillin, cefoxitin, gentamicin, or nalidixic acid, 150 or when combined with tazobactam/piperacillin.
158
In a study in rabbits of experimental endocarditis caused by a strain of K. pneumoniae producing a TEM-3 beta-lactamase and treated with fosfomycin + gentamicin combination, this combination appeared active while fosfomycin alone was not, gentamicin alone was active only in a highdose regimen, and in vitro combination was additive only (FIC index = 0.75). 146 
Netikul et al
159 pointed out that combination of fosfomycin with carbapenems was not synergistic (0.75 # FIC index # 2.0) against strains of E. coli or K. pneumoniae with decreased susceptibility to at least one carbapenem. In this study, the combination was assessed with the Etest, even though the Etest do not give reliable results for determination of the fosfomycin MIC in extended-spectrum β-lactamase-producing strains of K. pneumoniae. 9, 142, 143 With regard to multiresistant Enterobacteriaceae, there is a need for additional research because, in the event that a new extended-spectrum β-lactamase appears, the right partner for fosfomycin needs to be identified.
Drug Administration and Dosage intravenous administration
In severe infections in adults or children, the dose of fosfomycin administered is currently 100-200 mg/kg/day in 2-3 infusions per day. It may be doubled for a period in the treatment of central nervous system infections. Because fosfomycin 1 g provides 14.4 mEq of sodium, 5% glucose solutions should be used instead of saline solutions. Slow infusions over four hours are preferred because the drug concentration remains at a therapeutic level for a longer time, but infusions lasting a few minutes may be used, but with a risk of hypokalemia.
176
Few data are available in neonates. 153, 154, 177, 178 In a study performed in 10 neonates receiving 100 mg/kg intravenously twice a day, fosfomycin concentrations exceeded the MICs for most pathogens for over 12 hours after infusion, and the main pharmacokinetic parameters (peak plasma concentration, AUC, and half-life) were not significantly different between 30-minute or two-hour infusions. 179 In the event of renal impairment, no dose reduction is needed if creatinine clearance is above 60 mL/min. Below this value, the same dose is administered with a longer period between infusions, ie, 12 hours for 60 . 
Oral administration
A single dose of 3 g is currently used for the treatment of uncomplicated urinary tract infections. A 2 g dose has been proposed for the treatment of children, but this dose strength is not available everywhere. 183 In complicated urinary tract infections, when a longer duration of treatment is needed, some authors have proposed repeating three times the 3 g dose every other day. 184, 185 In cases of renal impairment, the dose does not need to be reduced.
48
Clinical Studies
Given the pharmacokinetic features and broadspectrum antibacterial activity of fosfomycin trometamine, a single dose can be proposed for the treatment of uncomplicated lower urinary tract infections. Its efficacy in this condition has been assessed by many studies and has been reviewed by several authors. 55, 186, 187 The studies were nonblinded, single-blinded, or doubleblinded comparisons. A single 3 g dose of fosfomycin was compared with single doses of amoxicillin 3 g, 188, 189 ofloxacin 200 mg, 190 norfloxacin 800 mg, 191 pefloxacin 800 mg, 192 trimethoprim 200 mg, 193 and cotrimoxazole 1920 mg. 190 A single dose of fosfomycin was also compared with amoxicillin + clavulanic acid 375 mg four times daily for five days, 194 cefalexin 500 mg four times daily for five days, 195 ciprofloxacin 500 mg twice daily for five days, 196 pipemidic acid 400 mg twice daily for 5-7 days, [197] [198] [199] norfloxacin 400 mg bid for 5-7 days, 197, [200] [201] [202] [203] cotrimoxazole 480 mg twice daily for three days, 204 trimethoprim 200 mg twice daily for five days, 18 and nitrofurantoin 50 mg four times daily for seven days. 205 In these studies, the microbiological and clinical efficacies were similar, and 70%-95% microbial eradication rates were observed 5-11 days after treatment.
Fosfomycin trometamine has also been investigated in pregnancy. In early studies, it was compared with nitrofurantoin and pipemidic acid in the treatment of lower urinary tract infections. 55, 199 More recently, it has been compared with ceftibuten 400 mg once daily for three days, with a 95% therapeutic success rate (clinical cure and bacteriological eradication). 206 In the treatment of asymptomatic bacteriuria, a single dose of fosfomycin trometamine showed the same level of therapeutic success as cefuroxime axetyl for five days (93.2% versus 95%), 207 and as amoxicillin + clavulanic acid for seven days (eradication rate over 80% in both groups). 208 A single 2 g dose of fosfomycin trometamine was also compared with pipemidic acid 200 mg twice daily for seven days in children weighing more than 25 kg. 183 Bacteriological results showed that at the end of follow-up (one month), urine was sterile in 70.8% and 70.3%, respectively, and the difference was not statistically significant.
Few data are available on the efficacy of intravenous fosfomycin as a single agent, 32, 209, 210 although this has been used widely in combination regimens to treat severe infections, mostly with beta-lactam antibiotics. Recent publications have demonstrated its activity as second-line treatment in limb-threatening diabetic foot infections, 211 and in pneumonia due to carbapenem-resistant P. aeruginosa. 212 
Multidrug-resistant Enterobacteriaceae
As a consequence of advancing drug resistance in common bacterial urinary pathogens and in the absence of new antimicrobial agents to treat them, a re-evaluation of fosfomycin has been undertaken by many investigators. 15, [19] [20] [21] [22] [23] [24] 213 Few new data are available as yet, but because fosfomycin is generally not affected by multidrug resistance, the old publications could offer some confidence in its efficacy while we await the results of ongoing studies. Table 7 presents the latest clinical results for multidrug-resistant Enterobacteriaceae. Senol et al 184 compared the efficacy of fosfomycin (three 3 g doses being taken orally, every other night) with that of a carbapenem, either imipenem cilastatin (0.5 g intravenously four times daily for 14 days) or meropenem (1 g intravenously three times daily for 14 days) in complicated urinary tract infections. Clinical and microbiological outcomes were similar in both groups, but the drug acquisition costs were very different. In the study by Rodriguez-Baño et al 214 one 3 g dose of fosfomycin trometamine was compared with amoxicillin + clavulanate (500/125 mg three times daily for 5-7 days), the overall cure rate was the same, but in the amoxicillin + clavulanate group, there was a significant difference (P = 0.02) according to the susceptibility level of the extendedspectrum β-lactamase strains of E. coli to amoxicillin and clavulanate, ie, with an MIC # 8 mg/L, 26 of 28 patients were cured (92.8%), while with MIC $ 16 mg/L, only five of nine patients were cured (55.5%). Although the study by Pullucku et al 185 was not randomized or controlled, its results sparked interest in fosfomycin trometamine with regard to extended-spectrum β-lactamase-producing E. coli in urinary tract infections with or without complicating factors.
The background to the study by Michalopoulos et al 215 was very different because it demonstrated interest in the use of intravenous fosfomycin in combination with other antibiotics for severe infections with extensively resistant strains of K. pneumoniae. The bacteriological and clinical outcomes in all 11 patients were good, and all-cause mortality was 18.2%.
A case report on gastroenteritis due to a multidrug-resistant strain of Salmonella typhimurium was reported as showing a complete response to fosfomycin, 216 but it is not possible to draw a conclusion or make a recommendation on the basis of a case report. Abbreviations: UTi, urinary tract infection; iCU, intensive care unit; CF, number of complicating factors; M, male; F, female; eSBL, extended spectrum β-lactamase;
MDR, multidrug resistant;
FT, fosfomycin trometamine; ipm, imipenem; Mer, meropenem; AMC, amoxicilline + clavulanic acid; Fos Na, sodium salt of fosfomycin; po, per os; iv, intravenous; /2 d: once every other day;
qid, four times daily; tid, three times daily; NR, not reported.
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Toxicity and Safety
The toxicity of both orally and intravenously administered fosfomycin is low. In comparative studies, drug-related adverse events were reported in .1% of the treated populations, ie, diarrhea 9.0%, vaginitis 5.5%, nausea 4.1%, headache 3.9%, dizziness 1.3%, asthenia 1.1%, and dyspepsia 1.1%. 217 Only diarrhea appeared more frequently in patients treated with fosfomycin than in those treated with nitrofurantoin, cotrimoxazole, or ciprofloxacin, but a new evaluation would be necessary now because the study was performed with the calcium salt of fosfomycin. For the other parameters, fosfomycin demonstrated rather fewer side effects. Adverse events with fosfomycin were usually mild and transient, lasting for a mean of 1.8 days. 55, 198, 201 No fetal toxicity was reported. The allergic risk is low. A single case report of anaphylactic shock was reported, 217 along with a single case report of liver toxicity during coadministration with imipenem (3 g daily) and parenteral nutrition with lipids and fosfomycin (12 g daily) in a female patient with cystic fibrosis. 61, 218 In a retrospective study of 72 intravenous fosfomycin courses, Florent et al 176 observed a 26% rate of hypokalemia, which was attributed to the 30-60-minute infusion and was not observed with the four-hour protocol. The mechanism involved might be distal tubular excretion of potassium with high doses of fosfomycin.
Patient Preference
Uncomplicated urinary tract infections are frequently observed in clinical practice. They are often treated without documentation but with a high probability of success. With the development of resistance, commonly used antibiotics, eg, amoxicillin, cotrimoxazole, and the quinolones, are showing decreasing activity, particularly since new mechanisms of resistance have been detected in the community. [12] [13] [14] 219 This resistance may be observed also in veterinary practice, 220 in sewage sludge and liquid pig manure, 221 and in cow excrement. 222 Given that the choice of a first-line treatment for uncomplicated urinary tract infection must be made according to the probability of success/failure, the likelihood of adverse effects, and cost considerations, fosfomycin appears to be a convenient option at the present time.
The risk factors for acquisition of multidrugresistant Enterobacteriaceae were defined a few years ago, ie, age over 50-65 years, 5, 39, 175, 214, 219 admission from a nursing home, 175, 214, 223 and previous antimicrobial therapy. 3, 7, 37, 175, 223 When these risk factors or complications are observed, documentation of infection is needed, and the choice of antibiotic therapy is made according to susceptibility, but fosfomycin appears to be an important agent for the treatment of such infections.
Conclusion
The dramatic increase in antimicrobial resistance of Enterobacteriaceae is of worldwide concern, with the frequent problem of extensively resistant strains. This situation has led to the search for alternative agents able to treat infections caused by these organisms. Some authors have proposed fosfomycin, an antibacterial agent that has shown very good activity against most strains of Enterobacteriaceae.
In uncomplicated urinary tract infections, a single oral dose is safe and effective, especially when multidrug-resistant strains are concerned. In complicated urinary tract infections, the same results can be achieved with several doses. In both situations, fosfomycin could be an interesting therapeutic option in that it limits the use of carbapenems for treating infections that could be cured at a lower cost, without increasing the risk of resistance. In severe infections, combinations with intravenous fosfomycin have proved to be effective in the past, but their future activity needs to be clarified because it depends on choosing the right partner drug. In any case, given the fast evolution of resistance, more studies are urgently needed.
